DBM

DBM Co., Ltd. is a South Korean biotechnology company specializing in the development of advanced drug delivery systems (DDS). The company's core technology, Bio-Matrix, enables the sustained release of various therapeutic agents, including small molecules and peptides, to improve patient compliance and therapeutic efficacy. DBM's pipeline focuses on chronic conditions such as type 2 diabetes, Alzheimer's disease, and osteoporosis, with lead candidates like DBM-101 (exenatide) and DBM-102 (donepezil). By leveraging its proprietary formulation expertise, DBM aims to transform existing injectable or short-acting drugs into long-acting, more convenient treatments.